Related Experiment Video
Updated: May 13, 2026

NF-κB-dependent Luciferase Activation and Quantification of Gene Expression in Salmonella Infected Tissue Culture Cells
Published on: January 12, 2020
The NF-κB RelB protein is an oncogenic driver of mesenchymal glioma
Dong Whan Lee1, Dhivya Ramakrishnan, John Valenta
1Department of Molecular & Cellular Medicine, Texas A&M University Health Science Center, College Station, Texas, United States of America.
Abstract:
High-grade gliomas, such as glioblastomas (GBMs), are very aggressive, invasive brain tumors with low patient survival rates. The recent identification of distinct glioma tumor subtypes offers the potential for understanding disease pathogenesis, responses to treatment and identification of molecular targets for personalized cancer therapies. However, the key alterations that drive tumorigenesis within each subtype are still poorly understood. Although aberrant NF-κB activity has been implicated in glioma, the roles of specific members of this protein family in tumorigenesis and pathogenesis have not been elucidated. In this study, we show that the NF-κB protein RelB is expressed in a particularly aggressive mesenchymal subtype of glioma, and loss of RelB significantly attenuated glioma cell survival, motility and invasion. We find that RelB promotes the expression of mesenchymal genes including YKL-40, a marker of the MES glioma subtype. Additionally, RelB regulates expression of Olig2, a regulator of cancer stem cell proliferation and a candidate marker for the cell of origin in glioma. Furthermore, loss of RelB in glioma cells significantly diminished tumor growth in orthotopic mouse xenografts. The relevance of our studies for human disease was confirmed by analysis of a human GBM genome database, which revealed that high RelB expression strongly correlates with rapid tumor progression and poor patient survival rates. Thus, our findings demonstrate that RelB is an oncogenic driver of mesenchymal glioma tumor growth and invasion, highlighting the therapeutic potential of inhibiting the noncanonical NF-κB (RelB-mediated) pathway to treat these deadly tumors.
Insights
The NF-κB protein RelB drives aggressive mesenchymal glioma growth and invasion. Inhibiting this pathway offers a potential new therapy for glioblastomas, improving patient survival rates.
Area of Science:
- Neuro-oncology
- Molecular biology
- Cancer research
Background:
- High-grade gliomas, including glioblastomas (GBMs), are aggressive brain tumors with poor prognoses.
- Distinct glioma subtypes are recognized, but the molecular drivers of tumorigenesis within each remain unclear.
- Aberrant nuclear factor-kappa B (NF-κB) activity is implicated in glioma, yet specific family member roles are not fully understood.
Purpose of the Study:
- To investigate the role of the NF-κB protein RelB in glioma pathogenesis, particularly within aggressive subtypes.
- To determine if RelB influences glioma cell survival, motility, invasion, and tumor growth.
- To assess the therapeutic potential of targeting the RelB-mediated pathway in mesenchymal gliomas.
Main Methods:
- Analysis of RelB expression in glioma subtypes.
- Functional studies involving RelB knockdown in glioma cells to assess effects on survival, motility, and invasion.
- Gene expression analysis to identify RelB-regulated genes (e.g., YKL-40, Olig2).
- In vivo studies using orthotopic mouse xenograft models.
- Correlation analysis with human glioblastoma genome database.
Main Results:
- RelB is expressed in aggressive mesenchymal glioma subtypes.
- Loss of RelB significantly reduced glioma cell survival, motility, and invasion.
- RelB promotes the expression of mesenchymal genes (YKL-40) and Olig2.
- RelB deficiency diminished tumor growth in mouse models.
- High RelB expression in human GBM correlates with rapid progression and poor survival.
Conclusions:
- RelB acts as an oncogenic driver in mesenchymal glioma.
- Targeting the noncanonical NF-κB (RelB-mediated) pathway presents a potential therapeutic strategy for aggressive gliomas.
- Understanding RelB's role opens avenues for personalized glioblastoma therapies.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
NF-kB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
The Ras Gene
Ras is a superfamily...
Induced Pluripotent Stem Cells
Somatic cells are...
